Cheng et al. reported that IBI939 plus sintilimab had a manageable safety profile and could improve PFS of patients with metastatic NSCLC and PD-L1 expression ≥ 50% compared with sintilimab alone (median, not reached vs. 6.0 months) [116]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.